CHITOSE Group Successfully Concludes Capital Increase of 21M USD Scale through Third-Party Allotment
14.9.2023 16:00:00 EEST | Business Wire | Press release
CHITOSE BIO EVOLUTION PTE. LTD., the leader of the global bioeconomy and the headquarters of the CHITOSE Group (hereinafter "CHITOSE"), has successfully concluded a total of 21M USD new share issuances through a third-party allotment with Shiseido Company, Limited, NGK INSULATORS, LTD., Mitsui Mining & Smelting Co. Ltd. (*1), Mitsubishi Kakoki Kaisha.Ltd., Amano Enzyme Inc., Mers Line Pte. Ltd. (*2), Ikeda tohka Industries Co., Ltd. and SHINSHO CORPORATION. The funds raised will be allocated towards the expansion of the microalgae production facility and R&D of product applications in order to accelerate MATSURI, the project to build a microalgae-based industry to replace the petroleum industry. Through these commitments, CHITOSE will contribute to the realization of zero carbon emissions and work together with others toward a prosperous future that will last beyond a thousand years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230914666208/en/
Microalgae Production Scale Roadmap (Graphic: Business Wire)
*1 Investment by Mitsui Kinzoku-SBI Material Innovation Fund with Mitsui Mining & Smelting Co. Ltd. as a Limited Partnership and SBI Investment as a General Partnership.
*2 Investment by Sun Sail Navigation Pte. Ltd., which belongs to the Mers Line Pte Ltd. group.
Rationale for the Capital Increase & Use of Proceeds
CHITOSE envisions a future in which humankind can live prosperously for the next thousand years and aims to build an unprecedented microalgae-derived industry. Working in collaboration with progressive companies and organizations spanning various sectors and industries, CHITOSE is simultaneously expanding the scale of production and developing multifaceted applications in order to promote the use of microalgae products in fuels, foods, chemical products, cosmetics, and feedstuffs that support people's lives.
In terms of scale-up of microalgae production facilities, following completion of a 0.1 hectare facility in August 2018, CHITOSE successfully inaugurated a 5 hectare-facility named CHITOSE Carbon Capture Central (C4) in April 2023. CHITOSE plans to expand it further to a scale of 2,000 hectares by 2030 and 10 million hectares by 2050. In the current fiscal year, CHITOSE has just launched the 2,000 hectare-project, of which the initial 100 hectare-facility development along with the R&D of various applications have been selected as a commissioned project by the Green Innovation Fund / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material (*3) of NEDO (*4).
*3 About the Green Innovation Fund Project / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material
https://green-innovation.nedo.go.jp/en/project/bio-manufacturing-technology/
*4 New Energy and Industrial Technology Development Organization
Future Procurement Plans
Growing expectations for stable procurement of resources and contribution to sustainable manufacturing enabled us to achieve our target of 20M USD for the current fiscal year during the first half of the year. Responding to strong market demand, CHITOSE intends to continue vigorous dialogue with investors in the second half of the year and beyond.
*Note: All figures are the exchange value of the USD calculated as of September 8, 2023.
Stakeholder’s Comments
Shiseido Company, Limited
"Under our mission of 'BEAUTY INNOVATIONS FOR A BETTER WORLD,' our company is committed to developing cosmetics that are not only good for the skin, but also promotes a healthy and beautiful natural environment. We are working with the CHITOSE Group to build a circular model, maximizing the potential of 'algae,' and integrating it into the earth's system, ensuring resources are not depleted. We will lead the creation of sustainable value, thereby revitalizing the global cosmetics market."
NGK INSULATORS, LTD.
"NGK, a member of MATSURI, is encouraged to develop algae business that contributes to carbon neutrality with our unique ceramic technologies. NGK and CHITOSE Group will extend our collaboration to realize social implementation of the bio industry."
Mitsui Mining & Smelting Co., Ltd.
"Mitsui Mining & Smelting Co., Ltd. is working to co-create a value chain for bio-manufacturing by applying our unique catalyst, separation and purification technologies in order to contribute to the realization of a sustainable society."
Mitsubishi Kakoki Kaisha, Ltd.
"Mitsubishi Kakoki Kaisha believes that algae can be a solution to the global food and energy problems, and this investment is in line with our long-term management vision. We will work closely with the MATSURI project and contribute to the development of the algae business with our technology."
Mers Line Pte. Ltd.
"With the utilization of microalgae, a carbon-free society is just around the corner. We sympathize with the philosophy of CHITOSE Group, 'To live in abundance beyond the next millennium using the ability of living things' and support their activities."
Ikeda tohka Industries Co.,Ltd.
"As a food ingredient manufacturer with over 100 years of history, we harness our cultivated food processing technology to convert algae biomass into a usable form for industries. Through this, we support the creation of a sustainable and carbon-neutral society."
SHINSHO CORPORATION
"Through this investment, we intend to collaborate with CHITOSE Group, in order to build a new resource-recycling business model through carbon recycling and new business development using microalgae."
###
About MATSURI
https://matsuri-partners.chitose-bio.com/en
The MATSURI project aims towards the establishment of an advanced microalgae-based industry. CHITOSE has considerable expertise in large-scale photosynthetic production technologies, and is leading the MATSURI project collaborating with Japanese progressive enterprises. As what MATSURI means in Japanese, CHITOSE keeps leading a festival to develop a sustainable society. If you are interested in MATSURI, please feel free to contact the MATSURI office. Click here to contact us.
Related Information
[Press Release] CHITOSE Group, Successfully Concludes Capital Increase of 7M USD Scale from Shiseido and Forms Strategic Partnership ― Accelerate a Microalgae-based Circular Manufacturing in a Cosmetic Industry —
[Press Release] CHITOSE Group Obtains Funding from Japanese Government(NEDO) for Green Innovation Fund of 400M USD Scale
[MATSURI partner site] Shiseido Company, Limited Joined MATSURI as a Corporate Partner (Japanese)
[MATSURI partner site]
Amano Enzyme Inc. Joined MATSURI as an Industry Restructuring Partner (Japanese)
CHITOSE Group Overview
https://chitose-bio.com/
CHITOSE Group is a family of biotechnology companies leading the global bioeconomy. To live in abundance beyond the next millennium using the ability of living things, CHITOSE pursues the possibilities of biotechnology through technological and business development collaborating with its business partners all over the world.
About CHITOSE BIO EVOLUTION PTE. LTD. (head office that oversees entire Group)
Established in October, 2011
Head Office located in Singapore
CEO: Tomohiro FUJITA, Ph. D.
About CHITOSE Laboratory Corp. (responsible for the project)
Established in November, 2002
Head Office located in Kanagawa Prefecture, Japan
CEO: Tomohiro FUJITA, Ph. D.
COO: Rie KUGIMIYA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914666208/en/
Contact information
Media Contact:
Communication Design Div.
CHITOSE Group
pr@chitose-bio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom